<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neil Kendle</title>
	<atom:link href="http://kendlehealthcare.com/blog/?feed=rss2" rel="self" type="application/rss+xml" />
	<link>http://kendlehealthcare.com/blog</link>
	<description>From the Experts On Experts</description>
	<lastBuildDate>Wed, 05 Oct 2011 09:10:14 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Why pharma must rethink KOL strategy for emerging markets</title>
		<link>http://kendlehealthcare.com/blog/?p=128</link>
		<comments>http://kendlehealthcare.com/blog/?p=128#comments</comments>
		<pubDate>Tue, 04 Oct 2011 13:32:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[BRIC-MT]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Kendle Healthcare]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>
		<category><![CDATA[market access]]></category>
		<category><![CDATA[Mexico]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[prescribers]]></category>
		<category><![CDATA[Russia]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[traditional medicine]]></category>
		<category><![CDATA[Turkey]]></category>

		<guid isPermaLink="false">http://kendlehealthcare.com/blog/?p=128</guid>
		<description><![CDATA[India, Brazil, China and other BRIC-MT countries are representative of an ever-evolving KOL landscape, particularly with regard to market access procedures.]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=128</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8220;Shades of grey&#8221;: the issues surrounding medical ghostwriting are not as black and white as some would have you think.</title>
		<link>http://kendlehealthcare.com/blog/?p=85</link>
		<comments>http://kendlehealthcare.com/blog/?p=85#comments</comments>
		<pubDate>Tue, 09 Aug 2011 10:18:54 +0000</pubDate>
		<dc:creator>NeilKendle</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[media]]></category>
		<category><![CDATA[opinion leaders]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://kendlehealthcare.com/blog/?p=85</guid>
		<description><![CDATA[The Guardian recently published an article about medical ghostwriting that commented on a paper calling for increased liability for academics who use “ghostwriters”.]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=85</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>The importance of training</title>
		<link>http://kendlehealthcare.com/blog/?p=71</link>
		<comments>http://kendlehealthcare.com/blog/?p=71#comments</comments>
		<pubDate>Tue, 10 May 2011 16:23:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[Kendle Healthcare]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[SMi]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workshops]]></category>

		<guid isPermaLink="false">http://kendlehealthcare.com/?p=71</guid>
		<description><![CDATA[A company would never sending a rep out without training them, so why are KOL-facing personnel often neglected when it comes to opinion leader engagement training?]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=71</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>KOL &amp; Stakeholder Engagement Europe Summit, May 2011</title>
		<link>http://kendlehealthcare.com/blog/?p=49</link>
		<comments>http://kendlehealthcare.com/blog/?p=49#comments</comments>
		<pubDate>Fri, 08 Apr 2011 09:57:27 +0000</pubDate>
		<dc:creator>NeilKendle</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[conference]]></category>
		<category><![CDATA[eyeforpharma]]></category>
		<category><![CDATA[Kendle Healthcare]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>

		<guid isPermaLink="false">http://www.asterisk.myzen.co.uk/kendle/blog/?p=49</guid>
		<description><![CDATA[I'm very much looking forward to chairing a day of eyeforpharma's KOL &#038; Stakeholder Engagement Summit in Berlin.]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=49</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A rose by any other name&#8230;.</title>
		<link>http://kendlehealthcare.com/blog/?p=38</link>
		<comments>http://kendlehealthcare.com/blog/?p=38#comments</comments>
		<pubDate>Fri, 11 Jun 2010 15:59:40 +0000</pubDate>
		<dc:creator>NeilKendle</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[external experts]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[opinion leaders]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Ray Moynihan]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.asterisk.myzen.co.uk/kendle/blog/?p=38</guid>
		<description><![CDATA[There is a view within the industry that we should avoid the term "opinion leader".  Does it matter if we call them something else? I think it does but avoiding the term is a practice that seems to be gaining some ground.  
]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=38</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will we need to disclose payments to individual KOLs ?</title>
		<link>http://kendlehealthcare.com/blog/?p=23</link>
		<comments>http://kendlehealthcare.com/blog/?p=23#comments</comments>
		<pubDate>Fri, 29 Jan 2010 16:27:23 +0000</pubDate>
		<dc:creator>NeilKendle</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Kendle Healthcare]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[media]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NHS]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[Royal college of Physicians]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.asterisk.myzen.co.uk/kendle/blog/?p=23</guid>
		<description><![CDATA[In some US states, Pharma companies now have to disclose how much they have paid individual doctors. Will this sort of mandatory transparency prevail in Europe?]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=23</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beware the pitfalls of &#8216;Fair Market Value&#8217;</title>
		<link>http://kendlehealthcare.com/blog/?p=9</link>
		<comments>http://kendlehealthcare.com/blog/?p=9#comments</comments>
		<pubDate>Thu, 27 Aug 2009 08:00:30 +0000</pubDate>
		<dc:creator>NeilKendle</dc:creator>
				<category><![CDATA[From the Experts On Experts]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[benchmarking]]></category>
		<category><![CDATA[emerging markets]]></category>
		<category><![CDATA[Fair market value]]></category>
		<category><![CDATA[FMV]]></category>
		<category><![CDATA[key opinion leaders]]></category>
		<category><![CDATA[KOLs]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.asterisk.myzen.co.uk/kendle/blog/?p=9</guid>
		<description><![CDATA[How many of us understand the concept of Fair Market Value and, if we don't, does it matter? ]]></description>
		<wfw:commentRss>http://kendlehealthcare.com/blog/?feed=rss2&#038;p=9</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

